Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Slightly Bullish +15

Novo Nordisk A/S $NVO Shares Bought by Bleakley Financial Group LLC

📈 Bleakley Financial Group LLC increased its NVO holdings by 20.9% in Q1 to own 75,618 shares worth $2.779 million.

📊 Other institutional investors like Quotient Wealth Partners and Certuity LLC also boosted their positions in the fourth quarter.

📉 Hedge funds collectively hold 11.54% of Novo Nordisk A/S stock as of the latest filings.

💰 The company has a market capitalization of $225.77 billion with a debt-to-equity ratio of 0.59.

📈 Analysts have issued mixed ratings including an 'outperform' from Sanford C. Bernstein and a 'peer perform' from Wolfe Research.

🎯 The consensus analyst target price for NVO is $65.56 with a current rating of 'Hold'.

📉 Wall Street Zen recently downgraded the stock from 'buy' to 'hold' in late June.

🏥 Novo Nordisk is a Danish multinational headquartered in Bagsværd, Denmark specializing in diabetes care.

📉 The stock has a 1-year low of $35.12 and a 1-year high of $71.79.

📊 Financial metrics include a PE ratio of 11.87, PEG ratio of 4.48, and beta of 0.77.

Bullish Signals
  • Bleakley Financial Group LLC significantly increased its stake by 20.9% in Q1, indicating strong institutional confidence.
  • Multiple other large investors including Quotient Wealth Partners and Certuity LLC also increased their holdings in the fourth quarter.
Risk Factors
  • Wall Street Zen downgraded the stock from 'buy' to 'hold' in late June, reflecting some analyst caution.
  • Citigroup reiterated a 'neutral' rating on the stock in mid-May, suggesting no immediate upside catalysts.
Full Analysis
Bleakley Financial Group LLC increased its holdings in Novo Nordisk A/S (NYSE: NVO) by 20.9% during the first quarter, purchasing an additional 13,075 shares to reach a total of 75,618 shares valued at $2.779 million according to recent SEC filings. Other institutional investors including Quotient Wealth Partners LLC, Certuity LLC, and Oakworth Capital Inc. also adjusted their positions in the fourth quarter, with most increasing their stakes while hedge funds collectively own 11.54% of the company's stock. Analyst sentiment remains mixed with a consensus rating of 'Hold' and a target price of $65.56, though recent downgrades from Wall Street Zen and Citigroup contrast with an 'outperform' rating from Sanford C. Bernstein. The article provides extensive financial metrics including a market cap of $225.77 billion, a PE ratio of 11.87, and current stock price data, alongside a company overview highlighting its Danish heritage and leadership in diabetes care.